Clinical relevance of CD10 expression in childhood ALL

Haematologica

Volumn 83, Issue 11, 1998, Pages 967-973

  Consolini, Rita ^a   Legitimo, Annalisa ^a   Rondelli, Roberto ^b   Guglielmi, Cesare ^c   Barisone, Elena ^d   Lippi, Alma ^e   Cantù Rajnoldi, Angelo ^f   Aricò, Maurizio ^g   Conter, Valentino ^f   Cocito, Maria Grazia ^g   Putti, Maria Caterina ^h   Pession, Andrea ^b   Masera, Giuseppe ^f   Biondi, Andrea ^f   Basso, Giuseppe ⁱ  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

CD10 acute lymphoblastic leukemia; Childhood

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE DISTRIBUTION; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLAST CELL; CANCER SURVIVAL; CELL LINEAGE; CHILD; CHILDHOOD DISEASE; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SEX DIFFERENCE; T LYMPHOCYTE;

ADOLESCENT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT; ITALY; LEUKEMIA, B-CELL; LEUKEMIA, CALLA-POSITIVE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LEUKEMIA, T-CELL; LIFE TABLES; MALE; NEPRILYSIN; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 0032446344     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Greaves MF, Brown C, Rapson NT, Lister TA. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol 1975; 4:67-84.
2. Letarte M, Vera S, Tran R, et al. Common acute lymphoblastic leukemia antigen is identical to neutral endopeptidase. J Exp Med 1988; 168:1247-53.
3. Greaves MF, Hairi G, Newman RA, Sutherland DR, Ritter MA, Ritz J. Selective expression of the common acute lymphoblastic leukemia (gp100) antigen on immature lymphoid cells and their malignant counterparts. Blood 1983; 61:628-39.
4. Cossman J, Neckers LM, Leonard WJ, Greene WC. Polymorphonuclear neutrophils express the common acute lymphoblastic leukemia antigen. J Exp Med 1983; 157:1064-9.
5. Sallan SE, Ritz J, Pesando J, et al. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood 1988; 55:395-402.
6. Rivera-Luna R, Cardenas-Cardos R, Leal-Leal C, et al. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience. Arch Med Res 1997; 28: 233-9.
7. Pullen DJ, Boyett JM, Crist WM, et al. Pediatric Oncology Group utilization of immunologic markers in designation of acute lymphoblastic leukemia subgroups: influence on treatment response. Ann NY Acad Sci USA 1984; 428:26-48.
8. Dowell BL, Borowitz MJ, Boyett JM, et al. Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group Study. Cancer 1987; 59:2020-6.
9. Pui C-H, Willliams DL, Raimondi SC, et al. Unfavorable presenting clinical and laboratory features are associated with CALLA-negative non-T, non-B lymphoblastic leukemia in children. Leuk Res 1986; 10: 1287-92.
10. Vannier JP, Bene MC, Faure GC, Bastard C, Garand R, Bernard A. Investigation of the CD10 (CALLA) negative acute lymphoblastic leukaemia: further description of a group with a poor prognosis . Br J Haematol 1989; 72:156-60.
11. Shuster JJ, Falletta JM, Pullen DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia. a Pediatric Oncology Group Study. Blood 1990; 75: 166-73.
12. Pui C-H, Behm FG, Singh B, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990; 75:174-9.
13. Pui C-H, Crist WM. High risk lymphoblastic leukemia in children: prognostic factors and management. Blood Rev 1987; 1:25-33.
14. Basso G, Rondelli R, Putti MC, et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: the experience of the AIEOP cooperative study. In: Ludwig WD, Thiel E, eds. Recent Results in Cancer Research. Berlin: Springer Verlag, 1993. p. 297-307.
15. Holowiecki J, Koehler M, Zintl Z, et al. On behalf of the International Society for Chemo-Immunotherapy (IGCI, Vienna) Cooperative Group. Childhood acute lymphoblastic leukemia immunopnenotypes and their prognostic significance: experience of the IGCI-study in 389 children. Leuk Lymphoma 1992; 7:225-34.
16. Pui C-H, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82:343-62.
17. Pui C-H, Rivera GK, Hancock ML, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic Leukemia 1993; 7:35-40.
18. Gibbson B, Katz FE, Gany P, Chessells JM. Infant acute lymphoblastic leukemia with t(11;19). Br J Haematol 1990; 74:264-9.
19. Stark B, Vogel R, Cohen JJ, et al. Biologic and cytogenetic characteristics of leukemia in infants. Cancer 1988; 63:117-25.
20. Basso G, Rondelli R, Covezzoli A, Putti MC. The role of immunophenotype in acute lymphoblastic leukemia of infant age. Leuk Lymphoma 1994; 15:51-60.
21. Paolucci G, Masera G, Vecchi V, Marsoni S, Pession A, Zurlo MG. Treating childhood acute lymphoblastic leukemia (ALL). Summary often years of experience in Italy. Med Pediatr Oncol 1989; 17:83-91.
22. Paolucci G, Masera G, Vecchi V, et al. Treatment of acute lymphoblastic leukemia in children: the Italian (AIEOP) experience. Bone Marrow Transplant 1989; 4(Suppl.1):95-7.
23. Conter V, Aricò M, Valsecchi MG, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk lymphoblastic leukemia treated with Berlin-Frankfurt-Munster based invasive chemotherapy. The Associazione Italiana di Ematologia e Oncologia Pediatrica. J Clin Oncol 1995; 13:2497-502.
24. Conter V, Schrappe M, Aricò M, et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol 1997; 15:2786-91.
25. Reiter A, Schrappe M, Ludwig D-W, et al. Chemotherapy in 988 unselected childhood acute lymphoblastic leukemia patients. Results and conclusion of the multicenter trial ALL-BFM86. Blood 1994; 84:3122-33.
26. Schrappe M, Reiter A, Sauter S, et al. Concept and interim results of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow. Klin Paediatr 1994; 206:208-21.
27. Bennet JM, Catovsky D, Daniel MT, et al. Proposal for the classification of the acute leukemias (French-British-American FAB Cooperative Group). Br J Haematol 1976; 33:451-8.
28. Van der Does-van den Berg A, Bartram CR, Basso G, et al. Minimal requirements for the diagnosis, classification and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the 2 BFM Family Cooperative Group. Med Pediatr Oncol 1992; 20:497-505.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
30. Mantel L, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-48.
31. Cox DR. Regression models and life-tables. J Roy Stat Soc 1972; B.34:187-220.
32. rd ed. Cambridge: University Press, 1966.
33. Aricò M, Basso G, Mandelli F, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica. Cancer 1995; 75:1684-93.
34. Uckun FM, Sather HN, Gaynon PS, et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia:a report from the Children's Cancer Group. Blood 1997; 90:28-35.
35. Putti MC, Rondelli R, Cocito MG, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia. Italian experience in AIEOP ALL 88-91 studies. Blood 1998; 92:1-9.
36. + B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma 1997; 27:445-57.
37. LeBien TW, McCormack RT. The commom acute lymphoblastic leukemia antigen (CD10). Emancipation from a functional enigma. Blood 1989; 73:625-35.
38. Salles G, Chen C-Y, Reinherz EL, Shipp MA. CD10/NEP is expressed on Thy-1 low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis. Blood 1992; 80:2021-9.
39. Malfroy B, Swertz JB, Guyon A, Roques BP, Schwartz JC. High affinity enkephalin-degrading peptidase in brain is increased after morphine. Nature 1978; 276: 523-6.
40. Shipp MA, Tarr GE, Chen C-Y, et al. CD10/Nep hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 1991; 88:10662-6.
41. - neutral endopeptidase 24.11. Nature 1990; 347:394-6.
42. Shipp MA, Stefano GB, Switzer SN, Griffin JD, Reinherz EL. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophils morphology, migration and adhesion proteins and is itself regulated by neutrophil activation. Blood 1991; 78:1834-41.
43. Matrisian LMG, Browden GT, Krieg P, et al. The mRNA coding for secreted protease transin is expressed more abundantly in malignant than in benign tumours. Proc Natl Acad Sci USA 1986; 83: 9413-7.
44. Shipp MA, Look TA. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting the key! Blood 1993; 82:1052-70.
45. Bené MC, Faure GC. CD10 in acute leukemias. Haematologica 1997; 82:205-10.